Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Agreement to develop E. coli O157:H7 vaccine
Researchers at work on the project in the Roslin Institute
Collaborative research enters commercial phase

Roslin Technologies has signed an agreement with animal sciences research establishments Moredun Research Institute, Scotland’s Rural College and the Roslin Institute at the University of Edinburgh, to fund the commercial development of an E. coli O157:H7 vaccine for cattle, which it is claimed will prevent illness in humans.

E. coli O157:H7 is a pathogenic bacterium of cattle that can cause life-threatening food-borne illness in humans through the consumption of contaminated products, such as dairy products and meat. Despite efforts to reduce contamination of food, E. coli O157:H7 causes one to 10 cases per 100,000 people, with certain countries having clusters of more virulent strains – notably the UK, USA, Argentina and Sweden.
 
The experimental vaccine has been developed to limit E. coli O157:H7 shedding from – and transmission between – cattle. Although the bacteria do not harm cattle, farmers will be encouraged to vaccinate animals against infection with this new vaccine. Early results have indicated that this vaccine may be more effective than other previous attempts and have a greater impact in reducing human exposure and infection.

The project team has been led by Dr Simon Wheeler COO of Roslin Technologies, with significant input from the principal investigators, Professor David Gally from Roslin Institute and Dr Tom McNeilly from Moredun Research Institute, who have been doing the fundamental research necessary to really understand whether the vaccine works and the essential science behind it.

Under the new agreement, Roslin Technologies will perform a two-step validation trial from May  to September 2020 in Nebraska, USA. The field trials will examine ‘super-shedding’ in cattle to discover whether the vaccine prevents shedding of the bacteria and is viable for commercial use.
 
The background research was funded  in part by UK agencies Defra (Department for Environment, Food & Rural Affairs), BBSRC (Biotechnology and Biological Sciences Research Council, FSA/FSS (Food Standards Agency/Food Standards Scotland), and other commercial partners. This valuable contribution is recognised by the project team.

Become a member or log in to add this story to your CPD history

Antibiotic Amnesty survey opens

News Story 1
 The Responsible Use of Medicines Alliance - Companion Animal and Equine (RUMA - CA&E) has launched a survey which seeks to measure the success of this year's Antibiotic Amnesty campaign.

Its results will help the group to calculate how many unused or out-of-date antibiotics were returned as part of the campaign throughout November. Practices are also asked how they engaged with clients to raise awareness of the issue.

Participating practices can enter a prize draw to win up to 100 in vouchers for taking part. Further prizes from BSAVA and Webinar Vet will be available for practices with the best input.

The survey takes a few minutes to complete and will be running throughout December. It can be accessed via this link

Click here for more...
News Shorts
Bluetongue cases lead to restricted zone extension

Following the detection of new cases of bluetongue virus serotype 3 (BTV-3), the restricted zone has been extended to include additional parts of Hampshire, Wiltshire, Oxfordshire and North Yorkshire, as well as Bournemouth, Christchurch, Poole and part of Dorset.

The zone now covers 28 counties and unitary authorities in England. As of 16 December, 185 cases of BTV-3 have been confirmed in England and Wales during the current vector period.

Bluetongue is a notifiable disease. Suspected cases must be reported on 03000 200 301 in England or 03003 038 268 in Wales. In Scotland, suspected cases should be reported to the local field services office. Suspected cases in Northern Ireland should be reported to the DAERA Helpline on 0300 200 7840 or by contacting the local DAERA Direct Veterinary Office.

A map of the area where movement restrictions apply can be found here.